Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

M B Smith; J Reardon; E M Olson

首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

【24h】

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

机译：帕妥珠单抗用于治疗先前未治疗的HER2阳性转移性乳腺癌患者。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pertuzumab is a humanized monoclonal antibody directed at the dimerization domain of the receptor tyrosine-protein kinase erbB-2 (HER2) receptor. It possesses a unique and complimentary mechanism of action compared to trastuzumab, which has historically been the cornerstone of therapy for HER2-amplified breast cancer. Clinical trials demonstrate improved outcomes, with minimal increases in toxicity with the addition of pertuzumab to trastuzumab in patients with HER2-positive metastatic breast cancer, indicating the advantage of dual HER2 receptor blockade. Pertuzumab is approved as first-line therapy in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer, with future opportunities to investigate its efficacy in other stages of breast cancer, as well as in the treatment of other malignancies.

机译：帕妥珠单抗是针对受体酪氨酸蛋白激酶erbB-2（HER2）受体二聚结构域的人源化单克隆抗体。与曲妥珠单抗相比，它具有独特而互补的作用机制，曲妥珠单抗历史上一直是HER2扩增乳腺癌治疗的基石。临床试验表明，HER2阳性转移性乳腺癌患者在曲妥珠单抗中添加了帕妥珠单抗后，其毒性改善最小，同时增加了曲妥珠单抗的毒性，表明双重HER2受体阻断的优势。帕妥珠单抗已被批准与曲妥珠单抗和多西他赛联合用于HER2阳性转移性乳腺癌的一线治疗，未来有机会研究其在乳腺癌其他阶段以及其他恶性肿瘤中的疗效。

著录项

来源
《Drugs of today: Medicamentos de actualidad》 |2012年第11期|共10页
作者
M B Smith; J Reardon; E M Olson;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer. [J] . M B Smith, J Reardon, E M Olson Drugs of today: Medicamentos de actualidad . 2012,第11期

机译：帕妥珠单抗用于治疗先前未治疗的HER2阳性转移性乳腺癌患者。
2. A Phase II, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxe! in Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla2期

机译：II期，随机，双盲，安慰剂对照的注册试验，用于评估帕妥珠单抗+曲妥珠单抗+多西他赛与安慰剂+曲妥珠单抗+多西他赛的疗效和安全性！未经治疗的HER2阳性转移性乳腺癌（CLEOPATRA）患者中
3. Taxane versus vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with metastatic HER2-positive breast cancer - A retrospective two-center study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：紫杉烷与血管联系相结合，与Pertuzumab和Trastuzumab进行了转移患者的一线治疗患者的转移性Her2阳性乳腺癌 - 一个回顾性的双中心研究
4. Ziconotide in the Treatment of Neuropathic Pain in a Patient with Metastatic Breast Cancer: A Case Report [C] . Eldabe S, Brookes M International Congress on Neuropathic Pain . 2010

机译：Ziconotide治疗转移性乳腺癌患者神经病疼痛的治疗：案例报告
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. PERTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER [O] . M.B. Smith, J. Reardon, E.M. Olson -1

机译：pertuzumab用于治疗以前未经治疗的HER2阳性转移性乳腺癌的患者
7. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) [O] . T. Sanglier, A. Fabi, C. Flores, 2019

机译：Hertuzumab + Trastuzumab（pH）患者在Her2阳性转移乳腺癌患者（MBC）中的使用后使用曲妥珠单抗（T-DM1; K）：评估现实世界中治疗测序的有效性的挑战（RW）

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

摘要

著录项

相似文献

相关主题

期刊订阅